Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

Sponsor

Augusta University (Other)

Overall Status

Unknown status

CT.gov ID

NCT03857581

Collaborator

(none)

100

Enrollment

Location

Arms

Anticipated Duration (Months)

8.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this trial is to determine if patients with comorbid psychotic disorder and substance use disorder will continue in treatment longer if treated with clozapine than with olanzapine, and will have greater reductions in psychosis and in substance use if treated with clozapine than treated with olanzapine. The specific aims and hypotheses of this trial are: 1. To compare the enduring effectiveness and tolerability of clozapine and olanzapine, as measured by time to all-cause treatment discontinuation, over 12 weeks of follow-up; The investigators hypothesize that patients assigned to clozapine treatment will have significantly longer times to all cause treatment discontinuation, 2. To compare the total psychosis items scores between patients treated with clozapine and patients treated with olanzapine over 12 weeks of follow-up; The investigators hypothesize that patients treated with clozapine will have significantly lower total psychosis items scores than patients treated with olanzapine, and 3. To compare the frequencies of positive urine drug screens and blood alcohol levels (obtained weekly throughout 12 weeks of follow-up) between patients treated with clozapine and patients treated with olanzapine; The investigators hypothesize that patients treated with clozapine will have significantly fewer positive urine drug screens and blood alcohol levels than patients treated with olanzapine.

Condition or Disease	Intervention/Treatment	Phase
Psychosis Substance Use Disorders	Drug: Clozapine Drug: Olanzapine	Phase 4

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

Anticipated Study Start Date :

Jul 1, 2020

Anticipated Primary Completion Date :

Jul 1, 2021

Anticipated Study Completion Date :

Jul 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Clozapine Arm	Drug: Clozapine Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
Active Comparator: Olanzapine Arm	Drug: Olanzapine Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.

Arm

Intervention/Treatment

Experimental: Clozapine Arm

Drug: Clozapine

Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.

Active Comparator: Olanzapine Arm

Drug: Olanzapine

Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.

Outcome Measures

Primary Outcome Measures

Frequencies of positive urine drug screens and breathalyzer alcohol levels [12 weeks]
Participants will have weekly urine drug screens and alcohol level measurement using breathalyzer to monitor ongoing substance and alcohol abuse.

Secondary Outcome Measures

All-cause treatment discontinuation [12 weeks]
Discontinuation rate due to any cause (treatment non-compliance, worsening of mental health conditions, withdrawal of consent)
Brief Psychiatric Rating Scale (BPRS) - Positive Psychopathology items [12 weeks]
BPRS scale is used to measure and monitor for symptoms of schizophrenia. For the purpose of the study, we will be measuring 4 items to monitor for positive psychopathology. The items are Suspiciousness Hallucinations Unusual thought content Conceptual disorganization Each item is rated on a scale of 1 to 7. 1 being condition not present and 7 being extreme form of the condition present. The maximum score a participant can score is 28 and minimum score is 4.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

18-60 years of age, male or female (post-menopausal, surgically sterilized, or receiving either one of the listed contraception - depot contraceptive, Intrauterine device, or implanted hormonal contraceptive),
who meet DSM-V criteria for schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, depression with psychotic features, or delusional disorder, and have ratings of Moderate or greater on at least one of the Brief Psychiatric Rating Scale psychosis items,
who meet DSM-V criteria for at least one of alcohol, marijuana, cocaine, stimulant, or opioid use disorder, and have an admission urine drug screen positive for at least one of these substances,
who have a stable living situation (family or supervised living, e.g. personal care home) to return to after release into the community,
and who provide signed informed consent to participate (after testing for comprehension).

Exclusion Criteria:

Prior failure to respond or tolerate clozapine or olanzapine
Logistics that prevent outpatient follow-up at Serenity Behavioral Health Adult Outpatient services